Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H1 2018, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.
Report Highlights Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 10, 6, 9, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2019, provides an overview of the Cognitive Impairment Associated With Schizophrenia...
Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019 Summary Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change...
Alpha Synuclein - Pipeline Review, H2 2019 Summary Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it...
Dyskinesia Global Clinical Trials Review, H1, 2019 Summary GlobalData’s clinical trial report, “Dyskinesia Global Clinical Trials Review, H1, 2019" provides an overview of Dyskinesia clinical trials scenario.This report provides top line data relating to the clinical trials on Dyskinesia. Report...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.